Abstract:
Objective To investigate the clinical efficacy and safety of liposome paclitaxel in maintenance therapy of advanced squamous cell lung carcinoma patients.
Methods After 4-6 cycles of first-line treatment, 57 patients with advanced squamous cell lung carcinoma were randomized into liposomal paclitaxel monotherapy maintenance treatment group(experimental group, n=29) and follow-up observation group(control group, n=28). Efficacy and side effects were observed in experimental group. PFS and OS were compared between two groups.
Results CR, PR, SD, PD rates of experimental group were 0, 13.8%, 44.8%, 41.4%, and disease control rate(DCR) was 58.6%. The major toxicities were myelosuppression and gastrointestinal reactions. PFS and median survival time(MST) of two groups were 5.7 vs. 2.4 months and 7.3 vs. 4.9 months(both P < 0.05). The patient's quality of life(QOL) was better in experimental group, compared with control group.
Conclusion As a maintenance therapy after the first-line treatment of advanced squamous cell lung carcinoma, liposomal paclitaxel could significantly improve PFS, OS and QOL of patients, and the adverse reactions are tolerable.